Nuevos anticoagulantes orales
Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the mos...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2011
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011001000016 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872011001000016 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720110010000162012-01-03Nuevos anticoagulantes oralesBerkovits,AlejandroAizman,AndrésZúñiga,PamelaPereira,JaimeMezzano,Diego Anticoagulants Haemostasis Thrombosis Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.10 20112011-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011001000016es10.4067/S0034-98872011001000016 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Anticoagulants Haemostasis Thrombosis |
| spellingShingle |
Anticoagulants Haemostasis Thrombosis Berkovits,Alejandro Aizman,Andrés Zúñiga,Pamela Pereira,Jaime Mezzano,Diego Nuevos anticoagulantes orales |
| description |
Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin. |
| author |
Berkovits,Alejandro Aizman,Andrés Zúñiga,Pamela Pereira,Jaime Mezzano,Diego |
| author_facet |
Berkovits,Alejandro Aizman,Andrés Zúñiga,Pamela Pereira,Jaime Mezzano,Diego |
| author_sort |
Berkovits,Alejandro |
| title |
Nuevos anticoagulantes orales |
| title_short |
Nuevos anticoagulantes orales |
| title_full |
Nuevos anticoagulantes orales |
| title_fullStr |
Nuevos anticoagulantes orales |
| title_full_unstemmed |
Nuevos anticoagulantes orales |
| title_sort |
nuevos anticoagulantes orales |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2011 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011001000016 |
| work_keys_str_mv |
AT berkovitsalejandro nuevosanticoagulantesorales AT aizmanandres nuevosanticoagulantesorales AT zunigapamela nuevosanticoagulantesorales AT pereirajaime nuevosanticoagulantesorales AT mezzanodiego nuevosanticoagulantesorales |
| _version_ |
1718436594011078656 |